Emraclidine for Schizophrenia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
Will I have to stop taking my current medications?
The trial requires participants to stop taking certain medications before and during the study, as there is a washout period (time without taking certain medications) specified. You should discuss with the trial team which of your current medications are considered prohibited.
Is Emraclidine safe for humans?
How is the drug Emraclidine different from other schizophrenia treatments?
Who Is on the Research Team?
Erica Koenig, PhD
Principal Investigator
Cerevel Therapeutics, LLC
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with schizophrenia who can understand the study and follow its procedures. It's not for those whose only response to treatment has been clozapine, or have progressive brain diseases, severe head trauma history, seizures (except childhood febrile seizures), or a high risk of suicide.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CVL-231 30 mg tablet once daily
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CVL-231
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cerevel Therapeutics, LLC
Lead Sponsor